NCT06175000View on ClinicalTrials.gov

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

September 15, 2028

Study Completion Date

September 15, 2029

Conditions
Primary Central Nervous System Lymphoma
Interventions
PROCEDURE

Cognitive Assessment

Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Quality of Life Assessment

Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.

Trial Locations (7)

10065

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

17033

RECRUITING

Pennsylvania State University, Hershey

22903

RECRUITING

University of Virginia, Charlottesville

44195

NOT_YET_RECRUITING

Cleveland Clinic, Cleveland

97225

RECRUITING

Providence Health & Services; Providence Neurological Specialties, Portland

98122

RECRUITING

Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute, Seattle

05405

RECRUITING

University of Vermont, Burlington

All Listed Sponsors
lead

Providence Health & Services

OTHER